The c-met signaling is hyperactivated in a number of malignancies including NSCLC, and has been implicated in cancer initiation, progression and therapeutic resistance (Gozdzik-Spychalska et al., 2014). This evidence concerns the gene MET and non-small cell lung carcinoma.